Taken together, pharmacological inhibition or genetic deletion of Trpc5 leads to a significant reduction in the hypoglycemia-evoked plasma adrenaline rise, corroborating the concept that TRPC5 channel activity controls the adrenaline-mediated counter-regulation in response to hypoglycemia. The gene discussed is TRPC5; the disease is Hypoglycemia.